Entera Bio (NASDAQ:ENTX) Issues Earnings Results
I'm PortAI, I can summarize articles.
Entera Bio (NASDAQ:ENTX) reported quarterly earnings of ($0.06) EPS, surpassing analysts' expectations of ($0.08) by $0.02. The stock traded down $0.05 to $1.75 with a market cap of $62.62 million. Analysts at HC Wainwright maintained a "buy" rating with a price target of $10.00. Entera Bio focuses on developing orally delivered peptide and protein therapeutics, with candidates in clinical trials for hypoparathyroidism and osteoporosis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments